Hepatic Encephalopathy Market, by Drug Class (Antibiotics, Laxatives, L-ornithine L-aspartate, and Others), by Route of Administration (Oral, Intravenous, and Rectal), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies

Hepatic Encephalopathy Market, by Drug Class (Antibiotics, Laxatives, L-ornithine L-aspartate, and Others), by Route of Administration (Oral, Intravenous, and Rectal), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Hepatic encephalopathy (HE) is the complication of advanced liver disease. Hepatic encephalopathy is a major challenge to the healthcare system due to frequent hospital contacts and admissions. Hepatic encephalopathy can be further divided into type A, type B, and type C that results from acute liver failure, portosystemic encephalopathy (PSS), and liver cirrhosis, respectively.
Market Dynamics
Key players are indulged in conducting clinical trials for the development of new therapeutic products for the treatment for liver diseases, which is expected to drive the global hepatic encephalopathy market growth over the forecast period. For instance, in December 2021, Kaleido Biosciences, Inc., a clinical-stage healthcare company announced positive results from a proof-of-concept clinical study, in which they used KB174, a novel microbiome metabolic therapy (MMT) in combination with a 15N-labeled tracer, a biomarker of microbiome ammonia production, in patients with liver cirrhosis. The treatment reduced the 15N urinary output and was well tolerated among the patients.
Market players are engaged in launching new products, in order to expand their market share, which is expected to spur growth of the market over the forecast period. For instance, in April 2015, Lupin Pharma Canada Limited, a subsidiary of Lupin Limited, launched Zaxine, indicated for the treatment of hepatic encephalopathy, under a strategic licensing agreement with the Salix Pharmaceuticals Inc. The agreement granted Lupin Pharma Canada Limited exclusive rights for the promotion, distribution, and marketing of Zaxine in Canada.
Key features of the study:
This report provides an in-depth analysis of global hepatic encephalopathy market, provides market size (US$ Million), and compound annual growth rate (CAGR %) for the forecast period (2022 - 2028), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategies adopted by the leading players
It profiles leading players in the global hepatic encephalopathy market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans
Key companies covered as a part of this study include ASKA Pharmaceutical Co., Ltd., Cosmo Pharmaceuticals N.V., Lupin Limited, Kaleido Biosciences, Kannalife Sciences, Inc., Bausch Health Companies Inc., Ferring Pharmaceuticals Inc., Mallinckrodt Pharmaceuticals, Umecrine Cognition AB, Norgine B.V., Abbott Laboratories, and QR Science and Technology Development Co. Ltd.
Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
The global hepatic encephalopathy market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision making through various strategy matrices used in analyzing the hepatic encephalopathy market.
Detailed Segmentation:
Global Hepatic Encephalopathy Market, By Drug Class:
Antibiotics
Laxatives
L-ornithine L-aspartate
Others
Global Hepatic Encephalopathy Market, By Route of Administration:
Oral
Intravenous
Rectal
Global Hepatic Encephalopathy Market, By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Global Hepatic Encephalopathy Market, By Region:
North America
By Country
U.S.
Canada
By Drug Class:
Antibiotics
Laxatives
L-ornithine L-aspartate
Others
By Route of Administration
Oral
Intravenous
Rectal
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Latin America
By Country:
Brazil
Mexico
Argentina
Rest of Latin America
By Drug Class:
Antibiotics
Laxatives
L-ornithine L-aspartate
Others
By Route of Administration
Oral
Intravenous
Rectal
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Europe
By Country:
U.K.
Germany
Italy
Spain
France
Russia
Rest of Europe
By Drug Class:
Antibiotics
Laxatives
L-ornithine L-aspartate
Others
By Route of Administration
Oral
Intravenous
Rectal
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Asia Pacific
By Country:
Australia
India
China
Japan
ASEAN
South Korea
Rest of Asia Pacific
By Drug Class:
Antibiotics
Laxatives
L-ornithine L-aspartate
Others
By Route of Administration
Oral
Intravenous
Rectal
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Middle East
By Country:
GCC
Israel
Rest of Middle East
By Drug Class:
Antibiotics
Laxatives
L-ornithine L-aspartate
Others
By Route of Administration
Oral
Intravenous
Rectal
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Africa
By Country/Region:
South Africa
Central Africa
North Africa
By Drug Class:
Antibiotics
Laxatives
L-ornithine L-aspartate
Others
By Route of Administration
Oral
Intravenous
Rectal
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Company Profiles
ASKA Pharmaceutical Co.*
Company Overview
Product Portfolio
Financial Performance
Recent Highlights
Strategies
Cosmo Pharmaceuticals N.V.
Lupin Limited
Kaleido Biosciences
Kannalife Sciences, Inc.
Bausch Health Companies Inc.
Ferring Pharmaceuticals Inc.
Mallinckrodt Pharmaceuticals
Umecrine Cognition AB
Norgine B.V.
Abbott Laboratories
QR Science and Technology Development Co. Ltd.
“*” marked represents similar segmentation in other categories in the respective section